

Article

Lycium Barbarum Polysaccharides and Wolfberry Juice Prevent DEHP-Induced Hepatotoxicity via PXR-Regulated Detoxification Pathway

Huan Liu † , Xiong Zhou † , Shaowen Huang, Jie Yang, Ruijing Liu and Chunhong Liu [*](https://orcid.org/0000-0003-4354-9151)

Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, Guangzhou 510642, China; m13710224344@163.com (H.L.); zhoucoon@163.com (X.Z.); seven060721@foxmail.com (S.H.); Judy_yang91@163.com (J.Y.); liuruijing1000@126.com (R.L.)

***** Correspondence: liuch@scau.edu.cn; Tel.: +86-020-8528-3448

† These authors contributed equally to this work and should be considered co-first authors.

Abstract: Environmental di(2-Ethylhexyl) phthalate (DEHP) is widely used in various industries as a plasticizer, and has been reported to induce reproductive and developmental toxicities in organisms. The purpose of this study was to evaluate the detoxification capacity of *Lycium barbarum* polysaccharides (LBP) and wolfberry juice (WJ) against DEHP-induced hepatotoxicity. Two groups of rats were purchased to study two different intervention method experiments: LBP (50, 100, 200 mg/kg·bw) intervention before DEHP (2000 mg/kg·bw) exposure, and LBP (200 mg/kg·bw) or WJ (8 mL/kg·bw) intervention after DEHP (3000 mg/kg·bw) exposure. The rats were exposed to DEHP once, while the intervention lasted for seven days. At the end of the intervention, enzymelinked immunosorbent assay (ELISA) was used to measure the related index. The LBP intervention before DEHP exposure experiment (the first experimental method) found that LBP group rats showed a strong capacity toward DEHP detoxification, evidenced by the significant upregulation of activities and concentrations of the partner retinoid, X receptor alpha ($RXRx$), and downstream regulators Cytochrome P4502E1 (CYP2E1), Cytochrome P4503A1 (CYP3A1), Glutathione S-Transferase Pi (GSTpi), and UDP-glucuronosyltransferase 1 (UGT1) in a dose-dependent manner. The LBP and WJ intervention after DEHP exposure experiment (the second intervention experiment) found that WJ could downregulate pregnane X receptor (PXR), and upregulate downstream regulators, CYP2E1, CYP3A1, and Glutathione S-Transferase (GST) with the extension of intervention time, to alleviate the toxicity of DEHP. However, the intervention effect of WJ was more obvious than that of LBP. These results suggested that LBP and WJ might be effective detoxification agents against DEHP-induced toxic effects, by activating PXR and PXR-related detoxifying enzymes.

Keywords: *Lycium barbarum* polysaccharides; wolfberry juice; di(2-Ethylhexyl) phthalate; pregnane X receptor; intervention

1. Introduction

Di(2-Ethylhexyl) phthalate (DEHP) is the most commonly used phthalate worldwide [\[1\]](#page-11-0). From Europe to Asia, DEHP is omnipresent and is commonly found in medical devices, household products, plastics, pharmaceutical preparations, food packaging, and industrial products. Since DEHP is toxic and ubiquitous in water, food, and air, it can be seen that it is very harmful to wildlife and human beings [\[2\]](#page-11-1). Di(2-Ethylhexyl) phthalate can disrupt endocrine function [\[3](#page-11-2)[,4\]](#page-11-3), and exposure to DEHP during the prenatal phase, infant phase, childhood, preadolescent phase, and post-adolescent phase causes severe harm to the body [\[5](#page-11-4)[–8\]](#page-11-5). At the same time, DEHP, as an environmental endocrine disruptor, also has embryotoxicity, immunotoxicity, genotoxicity, and neurotoxicity. Previous results showed that DEHP could damage the reproductive organs, blood, kidney, lung, and

Citation: Liu, H.; Zhou, X.; Huang, S.; Yang, J.; Liu, R.; Liu, C. Lycium Barbarum Polysaccharides and Wolfberry Juice Prevent DEHP-Induced Hepatotoxicity via PXR-Regulated Detoxification Pathway. *Molecules* **2021**, *26*, 859. [https://doi.org/10.3390/](https://doi.org/10.3390/molecules26040859) [molecules26040859](https://doi.org/10.3390/molecules26040859)

Academic Editor: Sylvia Colliec-Jouault Received: 13 January 2021 Accepted: 2 February 2021 Published: 6 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:/[/](https://creativecommons.org/licenses/by/4.0/) [creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/) $4.0/$).

liver of experimental animals [\[9\]](#page-11-6). Therefore, the United States Environmental Protection Agency (US EPA) and European Community (EC) regard DEHP as an environmental priority pollutant [\[10\]](#page-11-7). The reference dose (RfD), or tolerable daily intake (TDI), of DEHP is 20 mg/kg/d assessed by the US EPA (2007), and 37 mg/kg/d by the EU Scientific Committee for Toxicity, Ecotoxicity, and the Environment (CSTEE) [\[11\]](#page-11-8). So taking the omnipresence and toxicity of DEHP into consideration, the detoxication of such a contaminant seems especially important.

After entering the body, DEHP is first hydrolyzed into mono (2-Ethylhexyl) phthalate (MEHP) by biotransformation of phase I enzymes in the liver. Under the catalysis of UDPglucuronosyltransferase (UGT), these monoesters and oxidation products were converted into glucuronic acid by phase II biotransformation, which enhanced their water solubility and reduced their biological activity; and they were then metabolized and excreted from urine [\[12](#page-11-9)[–15\]](#page-11-10). Biotransformation of non-polar xenobiotics generally involves two systems, the phase I and phase II enzyme systems, with the most important system being the phase I system [\[16\]](#page-11-11). Key enzymes of the phase I system include the Cytochrome P450 (CYP450). Enzymes such as UGT and glutathione S-transferase (GST) play pivotal roles in the phase II conjugation reactions. Therefore, the quantity and/or activity of these key enzymes might be crucial in detoxication processes.

The pregnane X receptor (PXR), also known as the steroid and xenobiotic sensing nuclear receptor (SXR), is a protein that was discovered in 1998. The discovery of PXR provided a molecular basis for solving a long-standing problem in clinical medicine, of how specific drugs could induce pathways of drug clearance, and thereby enhance the rate of their own elimination, as well as co-administered drugs [\[17\]](#page-12-0). Pregnane X receptor (PXR) is the key to the body's response to toxic exogenous substances and endogenous metabolites. By acting as a ligand-activated transcription factor, PXR regulates all stages of heterobiotic metabolism and transport, and is responsible for the important induction of drug interactions [\[17\]](#page-12-0). Activation of human PXR (hPXR) results in transcriptional induction of Cytochrome P450 3A4 (CYP3A4) phase II hepatic biotransformation enzyme genes, i.e., those encoding UGTs and sulfotransferases (SULTs) [\[18\]](#page-12-1). Following ligand-binding, PXR forms a complex with its obligate heterodimeric partner the retinoid X receptor alpha (RXRα) or nuclear receptor subfamily 2, group B, member 1 (NR2B1), and then binds to response elements in the promoters and enhancers of the target genes [\[19\]](#page-12-2).

Lycium barbarum (LB), also known as Goji, is a popular ingredient in the preparation of traditional Chinese medicine [\[20\]](#page-12-3). LB is also known as wolfberry in the Western world, and has become studied for its health-promoting properties in recent years in Asia, Europe, and North America [\[21](#page-12-4)[–24\]](#page-12-5). *Lycium barbarum* extract, especially LB polysaccharides (LBP) is a renowned antioxidant, and has been reported on for its antioxidant capacity in various in vitro [\[25\]](#page-12-6), in vivo [\[26\]](#page-12-7), and clinical studies [\[27\]](#page-12-8). Previous studies have shown that LBP can reduce the DNA damage of non-insulin dependent diabetes mellitus (NIDDM) rats by reducing the level of oxidative stress [\[26\]](#page-12-7); it also significantly inhibited the peroxidation loss of β - carotene in β - carotene linoleic acid system; scavenged DPPH free radicals [\[25\]](#page-12-6); significantly improved the activities of Superoxide dismutase (SOD) and Gluthathione peroxidase (GSH-Px) in adult serum; and reduced the content of MDA [\[27\]](#page-12-8). *Lycium barbarum* polysaccharide (LBP), also has functions in, increasing immunity [\[28\]](#page-12-9), anticancer [\[29\]](#page-12-10), anti-aging [\[30\]](#page-12-11), and reproductive protection [\[31\]](#page-12-12). For example, LBP could significantly inhibit replicative senescence, and down regulate the senescence related genes [\[32\]](#page-12-13). In lipopolysaccharide (LPS) induced inflammation, LBP had a certain inhibitory effect on immune response [\[33\]](#page-12-14). *Lycium barbarum polysaccharide* could improve the retinal morphology and function of RD1 mice, and delay the functional decline of retinal ganglion cells in the process of photoreceptor degeneration [\[34\]](#page-12-15).

Taking their antioxidative capacity into consideration, exploring the intervention effects of LBP and wolfberry juice (WJ) on DEHP toxicity might be promising. The present study aimed to establish an animal model of DEHP exposure, and use LBP and WJ as the active intervention substance, as well as to investigate the effects of LBP and WJ on

PXR-mediated phase I and phase II metabolic enzyme activities following DEHP exposure. On this basis, we compared the effects of LBP and WJ on the repair of DEHP induced liver injury, and hope to provide a new method for improving liver injury.

2. Materials and Methods

2.1. Animals

A total of 120 male Sprague–Dawley (SD) rats, ranging in weight from 180–210 g, were purchased from Southern Medical University (Guangzhou, China). All experimental procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All animal tests were approved by the Animal Care Committee of the Laboratory Animal Center of South China Agricultural University, Guangzhou (#SCXK2011-0015). Animals were housed in stainless steel metabolic cages (one per cage) at constant room temperature (22 \pm 0.5 °C) and relative humidity (50–60%), with a 12 h:12 h light–dark cycle. All rats had access to food and water ad libitum.

2.2. Design

2.2.1. LBP Intervention before DEHP Exposure

After adaptation for 7 d, rats were divided into five groups (*n* = 8): control group (C), DEHP group (DEHP, 2000 mg DEHP/kg·bw), low-dose LBP intervention group (LBP-L, 2000 mg DEHP/kg·bw + 50 mg LBP/kg·bw), medium-dose LBP intervention group (LBP-M, 2000 mg DEHP/kg·bw + 100 mg LBP/kg·bw), and high-dose LBP intervention group (LBP-H, 2000 mg DEHP/kg·bw + 200 mg LBP/kg·bw). The LBP groups were given an indicated amount of LBP dissolved in saline by intragastric administration on a daily basis for 7 consecutive days, while the C group were treated with equal volumes of saline. At the 7th d after administration of LBP or saline, the rats were allowed to rest for one hour. After the rest, the DEHP and each of the LBP groups received a one-time gavage of 2000 mg DEHP/kg·bw dissolved in sesame oil, while the control group was treated with an equal volume of sesame oil. After a day off, the rats were sacrificed by a quick cervical dislocation. The serum was centrifuged after standing. Then, 1 g of liver was taken accurately, and washed with cold PBS. Then the liver was ground to prepare 10% liver homogenate, centrifuged (376 g, 20 min), and the supernatant was stored at −80 ◦C.

2.2.2. LBP and WJ Intervention after DEHP Exposure

After adaptation for 7 d, the rats were divided into four groups (*n* = 8): control group (C), DEHP group (DEHP, 3000 mg DEHP/kg·bw), high-dose LBP intervention group (LBP-H, 3000 mg DEHP/kg·bw + 200 mg LBP/kg·bw), and wolfberry juice group (WJ, 3000 mg DEHP/kg·bw + 8 mL/kg·bw WJ). On the first day, the DEHP, LBP-H, and WJ groups received a one-time gavage of 3000 mg DEHP/kg·bw dissolved in sesame oil, while the control group was treated with an equal volume of sesame oil (in order to cause more obvious toxicity, to observe the detoxification effect of LBP-H and WJ, the concentration of DEHP was changed to 3000 mg/kg·bw). The gavage volume was converted according to 4 mL/kg. Waiting 1 h after DEHP administration, the LBP-H and WJ groups were given an indicated amount of LBP and wolfberry juice dissolved in saline by intragastric administration. On the next six days, the LBP-H and WJ groups were given an indicated amount of LBP and wolfberry juice dissolved in saline by intragastric administration on a daily basis, while the control group were treated with equal volumes of saline. On the 1st, 3rd, 5th, and 7th day after gavage, 5 rats were randomly sacrificed by a quick cervical dislocation. Refer to Section [2.2.1](#page-2-0) for preparation of serum and liver homogenate samples.

2.3. Reagents

LBP was purchased from Shanghai Xian Pu Biological Technology Co. Ltd., Shanghai, China, Purity of the LBP was greater than 90%. WJ was purchased from Qinghai Dashu Red Medlar Co. Ltd., Qinghai, China.

2.4. ELISA Procedures P_A and P_A (EXT) C_A and C_A U_t . Generalistic sets and G is an algebra \mathcal{E} and \mathcal{E} and \mathcal{E} is an algebra \mathcal{E} and \mathcal{E}

2.4. ELISA Procedures

The hepatic activity of SOD, Glutathione (GSH), GSH-Px, Malondialdehyde (MDA), PXR, RXRα, CYP450, Cytochrome P450 2E1 (CYP2E1), Cytochrome P450 3A1 (CYP3A1), UGT1, GST, and Glutathione S-Transferase Pi (GSTpi) was analyzed using commercial ELISA kits, according to the manufacturers' instructions (Laibio, Shanghai, China). A double antibody sandwich method was used. In the process of determination, the purified rat antibodies (SOD, GSH, GSH-Px, MDA, PXR, RXRα, CYP450, CYP2E1, CYP3A1, UGT1, GST, and GSTpi in the kit) reacted only with the corresponding antibodies in the samples. After adding enzyme labeled antigen or antibody, the substrate was catalyzed into colored products by enzyme. The content of the product was directly related to the content of the tested substance in the standard. Then, the concentrations of SOD, GSH, GSH-Px, MDA, PXR, RXRα, CYP450, CYP2E1, CYP3A1, UGT1, GST, and GSTpi were determined
2.5. Statistical Analysis and CST by comparing the outer diameter of the sample with the standard curve.

2.5. Statistical Analysis **Analyze data analyze data analyzis** and make graphs, respectively. Experimental and ma

All raw data were collated in a Microsoft Excel database, whilst SPSS 18.0 and Graphpad Prism were used to analyze data and make graphs, respectively. Experimental data were expressed as means \pm standard deviation (means \pm SD). Differences among groups were compared with one-way analysis of variance. The significant difference level was accepted at $p < 0.05$, and the extremely significant difference level was accepted at $p < 0.01$.

3. Results *3.1. Effects of LBP Intervention before DEHP Exposure on Serum and Liver Oxidative Stress*

3.1. Effects of LBP Intervention before DEHP Exposure on Serum and Liver Oxidative Stress Index Index in Rats in Rats $A_{\rm 2D}$ shown in Figure 1A, the activity of server Δ

As shown in Figure [1A](#page-3-0), the activity of serum SOD in the LBP-L, LBP-M, and LBP-H groups was significantly increased ($p < 0.05$) compared with the control group and DEHP. The liver SOD activity of the LBP-M and LBP-H groups was higher than those of the control group and DEHP group ($p < 0.05$). With the intervention with LBP, the activity of SOD increased in a dose-dependent manner.

Figure 1. Effects of *Lycium barbarum* polysaccharide (LBP) intervention before Di(2-Ethylhexyl) phthalate (DEHP) exposure on serum and liver oxidative stress index in rats (*n* = 8). *Lycium barbarum* polysaccharide was continuously given for seven days, and DEHP was fed on the last day. The related oxidative stress indexes (SOD, SGH-Px, MDA) in serum and liver were determined by ELISA kit. (**A**,**D**): activities of SOD in serum and liver, respectively. (**B**,**E**): activities of GSH-Px in serum and liver, respectively. (**C**,**F**): concentrations of MDA in serum and liver, respectively. Data are expressed by mean ± S.D. The significance of difference among treatment groups was determined by one-way ANOVA. * or **: compared with control group, $p < 0.05$ or 0.01 ; $\#$ or $\#$: compared with DEHP group, $p < 0.05$ or 0.01.

3.2. Effects of LBP Intervention before DEHP Exposure on Liver Metabolic Enzyme Activities *in Rats* $\sum_{i=1}^{n}$ CYP₄₅

The effects of LBP intervention on the liver phase I and phase II enzyme activities of CYP2E1, CYP3A1, CYP450, GST-pi, and UGT1 in the rats are shown in Figure 2. Compared with the control group, the activities or concentrations of CYP2E1, CYP3A1, CYP450, GSTpi, and UGT1 in the DEHP group were significantly decreased ($p < 0.01$ or $p < 0.05$). With the intervention with LBP, the activity of all phase I and phase II enzymes, except GSTpi, increased in a dose-dependent manner. The activities of $\text{CYP2E1}, \text{CYP3A1},$ and CYP450 were significantly lower than those in the control group. The activities of CYP2E1, CYP3A1, CYP1A1, and UGT1 in the LBP-H group were significantly higher than those in the DEHP group ($\frac{1}{2}$ group ($p < 0.01$ to $p < 0.05$), while the activity of GSTpi in the LBP-M and LBP-H groups was significantly higher than that in the DEHP group (*p <* 0.05). The activity of UGT1 in (*p <* 0.05). the LBP-H group was significantly higher than that in the DEHP group (*p <* 0.05).

barbarum polysaccharide was continuously given for seven days, and DEHP was fed on the last day. The related liver **barbarum polysics** given for seven for seven for seven days, and DEHP was federal was federal to the related liver metabolic enzyme activities (CYP2E1, CYP3A1, CYP1A1, CYP450, GSTpi, and UGT1) were determined by ELISA kit. (A–F): Concentrations or activities of CYP2E1, CYP3A1, CYP1A1, CYP450, GSTpi and UGT1 in liver, respectively. Data are expressed by mean \pm S.D. The significance of differences among treatment groups was determined by one-way ANOVA. * or **: compared with control group, $p < 0.05$ or 0.01 ; $\#$ or $\#$: compared with DEHP group, $p < 0.05$ or 0.01 . **Figure 2.** Effects of LBP intervention before DEHP exposure on liver metabolic enzyme activities in rats (*n* = 8). *Lycium*

3.3. Effects of LBP Intervention before DEHP Exposure on PXR Concentration in Rats 3.3. Effects of LBP Intervention before DEHP Exposure on PXR Concentration in Rats

The effects of LBP intervention on PXR concentration in the rats are shown in Figure The effects of LBP intervention on PXR concentration in the rats are shown in Figure [3A](#page-5-0). 3A. Pregnane X receptor concentration in the DEHP group was lower than that in the group, but the difference was not significant. The PXR concentrations of LBP-L, M, and control group, but the difference was not significant. The PXR concentrations of LBP-L, H group were higher than those of the DEHP group (*p* < 0.05). The PXR concentration Pregnane X receptor concentration in the DEHP group was lower than that in the control increased with the intervention dose, but the difference was not significant. Similarly, the $PXR\alpha$ concentration of the DEHP group was lower than that of the control group, but the difference was not significant. The PXRα concentration increased with the increase of the intervention dose, and the concentrations of $PXR\alpha$ in the LBP-M and LBP-H groups were significantly higher than in the DEHP group (*p* < 0.05).

were significantly higher than in the DEHP group (*p* < 0.05).

polysaccharide was continuously given for seven days, and DEHP was fed on the last day. The related liver metabolic polysaccharide was continuously given for seven days, and DEHP was fed on the last day. The related liver metabolic enzyme activities (PXR and PXR α) were determined by ELISA kit. (A) or (B): concentrations of RXR or PXR α . Data are expressed by mean ± S.D. The significance of difference among treatment groups was determined by one-way ANOVA. expressed by mean ± S.D. The significance of difference among treatment groups was determined by one-way ANOVA. #: compared with DEHP group, *p <* 0.05. #: compared with DEHP group, *p <* 0.05. **Figure 3.** Effect of LBP intervention before DEHP exposure on transcriptional regulators in rats (*n* = 8). *Lycium barbarum*

3.4. Effects of LBP and WJ Intervention after DEHP Exposure on Serum Oxidative Stress Index 3.4. Effects of LBP and WJ Intervention after DEHP Exposure on Serum Oxidative Stress Index in in Rats Exposed to DEHP Rats Exposed to DEHP

The effects of LBP and WJ intervention on serum SOD, GSH-Px, GSH, and MDA in The effects of LBP and WJ intervention on serum SOD, GSH-Px, GSH, and MDA in the check of DDF are shown in Figure 4. On the third day, the third day, the third day, the third day, the $\frac{1}{2}$ the rats exposed to DEHP are shown in Figure [4.](#page-5-1) On the third day, the SOD and GSH-PX activity in the DEHP group was lower compared with the control group ($p < 0.05$), and the activities of SOD and GSH-Px in the LBP-H and WJ groups were increased when compared with the DEHP group ($p < 0.01$). Compared with the DEHP group on the 5th and 7th day, the GSH-Px activity in the LBP-H group was significantly higher ($p < 0.05$). In addition, the *M* group augmented the levels of GSH-Px compared with the control group and DEHP group on the seventh day ($p < 0.05$).

Figure 4. Effects of LBP and wolfberry juice (WJ) intervention on serum oxidative stress index in exposed to DEHP ($n = 8$). After one day of DEHP feeding, LBP and WJ were used for continuous intervention, and the serum oxidative stress indexes (SOD, SGH-Px, GSH, MDA) were measured by ELISA kit on the first, third, fifth, and seventh day of intervention. (A-D): concentrations and activities \overline{C} COD, GCH-P_x, GSH-Px, \overline{C} of SOD, GSH-Px, GSH, or MDA in serum, respectively. Note: data are expressed by mean \pm S.D. The significance of difference among treatment groups was determined by one-way ANOVA. $*$ or $**$: compared with control group, $p < 0.05$ or 0.01 ; $\#$ or $\#$: compared with DEHP group, $p < 0.05$ or 0.01. **Figure 4.** Effects of LBP and wolfberry juice (WJ) intervention on serum oxidative stress index in rats

3.5. Effects of LBP and WJ Intervention after DEHP Exposure on Liver Oxidative Stress Index in *in Rats Exposed to DEHP Rats Exposed to DEHP*

As shown in Figure 5A, on the first day the activity of SOD in the LBP-H group was As shown in Figure [5A](#page-6-0), on the first day the activity of SOD in the LBP-H group was markedly higher than that of the control group $(p \le 0.05)$; On the third day markedly higher than that of the control group ($p < 0.05$); On the third day, DEHP, LBP-H,

and WJ had markedly elevated SOD activity compared with the control group (*p <* 0.01); the high-dose LBP intervention group (LBP-H) had significantly increased activity of SOD compared to the DEHP group $(p < 0.01)$, while treatment with WJ had the opposite effect (*p <* 0.01). On fifth day the activity of SOD in the DEHP and WJ groups was significantly higher than that of control group $(p < 0.01)$; wolfberry juice markedly inhibited the activity of SOD compared with the DEHP group $(p < 0.01)$. On the seventh day DEHP, LBP-H, and WJ markedly elevated the activity of SOD compared with control group (*p* < 0.01). As shown in Figure [5B](#page-6-0), on the first day the activities of GSH-Px in the DEHP, LBP-H, and WJ groups were significantly higher than that of the control group (*p* < 0.05). On the third day the DEHP and LBP-H groups had significantly increased GSH-Px activity compared with the control group ($p < 0.05$), while WJ significantly decreased GSH-Px activity compared with the DEHP group $(p \lt 0.01)$. On the fifth day, compared with the control group, the activity of GSH-PX in the LBP-H group was significantly higher $(p < 0.05)$, while WJ significantly decreased GSH-Px activity compared with the DEHP group (*p* < 0.05). On the seventh day, LBP-H significantly increased the activity of GSH-Px compared with the DEHP group ($p < 0.05$). As shown in Figure [5C](#page-6-0), on the first day WJ significantly decreased the activity of GSH compared with the control group ($p < 0.05$). On the third day the activity of GSH in the DEHP group was significantly higher than that of the control group (*p* < 0.05), and WJ significantly decreased GSH activity compared with the DEHP group (*p* < 0.05). On the seventh day the activity of GSH in the WJ group was significantly lower compared with the control and DEHP groups ($p < 0.05$). As shown in Figure [5D](#page-6-0), on the third day LBP-H and WJ significantly decreased the level of MDA compared with the control group($p < 0.05$), and the concentration of MDA was significantly lower than that of the DEHP group ($p < 0.01$). On the seventh day DEHP significantly increased the level of MDA compared with the control group ($p < 0.01$), while WJ significantly decreased the level of MDA compared with the DEHP group (*p* < 0.05).

of DEHP feeding, LBP and WJ were used for continuous intervention, and the liver oxidative stress indexes (SOD, SGH-Px, of DEHP feeding, LBP and WJ were used for continuous intervention, and the liver oxidative stress indexes (SOD, SGH-GSH, MDA) were measured by ELISA kit on the first, third, fifth, and seventh day of intervention. (**A–D**): concentrations and activities of SOD, GSH-Px, GSH, and MDA in liver, respectively. Note: data are expressed by mean \pm S.D. The significance of differences among treatment groups was determined by one-way ANOVA. * or **: compared with the control group, $p < 0.05$ or 0.01 ; $\#$ or $\#$: compared with DEHP group, $p < 0.05$ or 0.01. **Figure 5.** Effects of LBP and WJ intervention on liver oxidative stress index in rats exposed to DEHP (*n* = 5). After one day

3.6. Effects of LBP and WJ Intervention after DEHP Exposure on Liver Metabolic Enzyme Activities in Rats Exposed to DEHP

As shown in Figure [6A](#page-7-0), on the fifth day the levels of P450 in the LBP-H group and WJ group were markedly higher than those of the control group ($p < 0.05$). As shown in Figure [6B](#page-7-0), on the fifth day compared with the control group and DEHP group, WJ markedly elevated the concentrations of CYP2E1 ($p < 0.05$); As shown in Figure [6D](#page-7-0), on the fifth day LBP-H and WJ markedly increased the levels of CYP2E1 compared with the control group and DEHP group ($p < 0.05$). As shown in Figure [6F](#page-7-0), on the first day WJ markedly increased the GST activity over that of the control group (*p* < 0.05). On the third day the activity of GST in the DEHP group, LBP-H group, and WJ group was markedly higher than that of the control group (*p* < 0.01), and WJ markedly increased the activity of GST compared with the DEHP group($p < 0.05$). On fifth and seventh days the activity of GST in the DEHP group, LBP-H group, and WJ group was markedly higher compared to the control group ($p < 0.05$).

one day of DEHP feeding, LBP and WJ were used for continuous intervention, and the liver metabolic enzymes (CYP450, CYP2E1, CYP1A1, CYP3A1, GSTpi, and GST) were measured by ELISA kit on the first, third, fifth, and seventh day of intervention. (A-F): concentrations and activities of CYP450, CYP2E1, CYP1A1, CYP3A1, GSTpi, and GST in liver, intervention. (**A**), (**B**), (**C**), (**D**), (**E**) and (**F**): concentrations and activities of CYP450, CYP2E1, CYP1A1, CYP3A1, GSTpi, respectively. Note: data are expressed by mean \pm S.D. The significance of differences among treatment groups was determined by one-way ANOVA. * or **: compared with control group, $p < 0.05$ or 0.01; $^{\#}$ or $^{\#}$: compared with DEHP DEHP group, *p* < 0.05 or 0.01. group, *p* < 0.05 or 0.01.**Figure 6.** Effects of LBP and WJ intervention on liver metabolic enzyme exposed to DEHP activity in rats (*n* = 5). After

3.7. Effects of LBP and WJ Intervention after DEHP Exposure on PXR Activity in Rats Exposed to DEHP

As shown in Figure [7A](#page-8-0), on the first day the levels of PXR in the LBP-H group and WJ group were significantly higher compared with the control group and DEHP group (*p* < 0.05). On the third day DEHP, LBP-H, and WJ significantly augmented PXR levels compared with the control group ($p < 0.05$), and LBP-H significantly increased the PXR concentration compared with the DEHP group ($p < 0.05$). On the fifth day the levels of PXR in the WJ group were significantly lower than those of the DEHP group (*p* < 0.05), and DEHP and LBP-H significantly increased PXR levels compared with the control group $(p < 0.01)$. As shown in Figure [7B](#page-8-0), on the first day DEHP significantly decreased the levels of PXRα compared with the control group (*p* < 0.05), while LBP-H and WJ significantly increased the levels of PXR α compared with the DEHP group ($p < 0.05$). On the third day DEHP increased PXR α concentrations compared to control ($p < 0.05$), and the level of WJ was significantly lower than that of the DEHP group ($p < 0.01$). On fifth day WJ significantly decreased PXR α levels compared with the DEHP group ($p < 0.05$). On the seventh day WJ significantly decreased PXRα concentrations compared with the control group and DEHP group $(p < 0.01)$.

day of DEHP feeding, LBP and WJ were used for continuous intervention, and the transcriptional regulator activity (PXR one day of DEHP feeding, LBP and Windows intervention of the transcription of the transcription of the transcription of and PXR α) was measured by ELISA kit on the first, third, fifth, and seventh day of intervention. This is the concentration of PXR(A) and PXR α (B), respectively. Note: data are expressed by mean \pm S.D. The significance of differences among treatment groups was determined by one-way ANOVA. * or **: compared with control group, $p < 0.05$ or 0.01 ; # or ##: compared with DEHP group, $p < 0.05$ or 0.01. **Figure 7.** Effects of LBP and WJ intervention on transcriptional regulator activity in rats exposed to DEHP (*n* = 5). After one

4. Discussion 4. Discussion

4.1. LBP Intervention before DEHP Exposure 4.1. LBP Intervention before DEHP Exposure

The analysis of oxidative damage in the rats before exposure showed that the SOD The analysis of oxidative damage in the rats before exposure showed that the SOD and GSH-Px activity of the serum and liver did not significantly alter, and the concentrations of MDA also did not change significantly, which indicated that DEHP did not cause obvious oxidative damage to the rats at the initial stage of exposure. However, LBP intervention can improve the SOD activity of the serum and liver, and enhance the antioxidant capacity of rats. $\sum_{n=1}^{\infty}$

DEHP is a lipophilic compound with high absorption upon oral exposure. Cytochrome P450 determines the rate of exogenous clearance and the production of toxic (carcinogenic) products, whilst the CYP1, CYP2, and CYP3 families mediate the metabolism of the vast majority of xenobiotics in the human body. Among them, inducing the cytochrome P450 enzymatic system has been proposed to be one of the most sensitive biological responses for responding to environmental changes. A previous study showed that DEHP exposure
for 7 A at a days of 1700 ms (locked in groups) that a third of GYP450, GYP251, and DEHP exposure for 7 d at a dose of 1700 mg/kg.bw, increased the activity of CYP450, CYP3A1, and reduced the activity of CYP1A1 in male rats [\[35](#page-12-16)[,36\]](#page-12-17). Their use of DEHP dose was close to ours, and the results were similar. In the current study, the activity dose was close to ours, and the results were similar. In the current study, the activity \sim 0.000 matrices were was constant and the results were similar the results of \sim 0.000 matrices of of CYP2E1, CYP3A1, and CYP450 in the DEHP group was significantly decreased, and for 7 d at a dose of 1700 mg/kg·bw, increased the activity of CYP450, CYP2E1, and

no significant difference was found for CYP1A1. The discrepancies in results between the studies might be due to different exposure times and doses of DEHP. The activity of phase I metabolic enzymes gradually increased with an increase in exposure time. For example, Chen et al. treated HepG2 cells with DEHP for 24 h and 48 h, and the levels of CYP1A1 and CYP3A4 were different for the two time periods [\[37\]](#page-12-18). Glucuronic-acid binding is an important phase II metabolic pathway in the organism, mainly catalyzed by UGT. The liver is the major organ of glucuronidation. UGTs are mainly expressed in the liver, and a large number of glucuronidation reactions occur in this organ [\[38\]](#page-12-19). The cytosolic glutathione S-transferases (GSTs) protect cells against various xenobiotic, electrophilic compounds through conjugation with glutathione. This renders these toxins less harmful to the cells, and facilitates their excretion [\[39\]](#page-12-20). The relatively high concentrations of environmental pollutant residues found in rats are catalyzed by phase II detoxifying enzymes, GSTs and UGT, and metabolism mainly occurs in the liver. The catalyzed products are water-soluble metabolites, which are discharged with bile or urine to achieve detoxification [\[40\]](#page-12-21). Burghll et al. suggested that UGT could be divided into UGT1 and UGT2 families [\[41\]](#page-12-22), which are involved in the metabolism of exogenous chemicals (such as phenol), and endogenous bilirubin metabolism and steroid metabolism. The UGT1 and UGT2 families can be divided into many subfamilies. Glutathione-S-transferases pi (GSTpi) is one of the GST isoenzymes. GSTpi is a phase II detoxifying enzyme that protects cells from injury caused by toxic chemicals and products of oxidative stress. In humans, polymorphisms of GSTpi affect substrate selectivity and stability, and increase susceptibility to the parkinsonism-inducing effects of environmental toxins [\[42\]](#page-12-23). Therefore, it is necessary to explore the toxic effects of DEHP on GSTpi and UGT1 in rat liver, and the detoxification effects of LBP on DEHP exposure. He et al. found that when SD rats were exposed to a single dose of 3000 mg/kg DEHP, the content of liver UGT1 decreased 24 h later [\[43\]](#page-12-24). Rataj et al. found that exposure to 4 ug/kg·bw 17 β -estradiol (E2) for 3 d inhibited uterine UGT1 expression to 26% of the baseline in ovariectomized rats [\[44\]](#page-12-25). Different studies in vivo and in vitro have demonstrated that DEHP has a weak estrogenic activity. Eveillard et al. found that the expression of GSTpi decreased by 2.4-fold after exposure of 15-week-old mice to 1100 mg/kg·bw DEHP for 14 d [\[14\]](#page-11-12). In the present study using the intragastric administration of 2000 mg/kg DEHP, we found that the activities of UGT1 and GSTpi decreased, which is consistent with previous studies. After consulting the relevant literature on LBP intervention, it was found that the most used concentration was 100 mg/kg [\[45\]](#page-12-26), so we set three doses of 50, 100, and 200 mg/kg on this basis. LBP high-dose intervention could significantly upregulate the activities of GSTpi and UGT1. These findings indicated that LBP intervention could antagonize the phase II enzyme damage induced by DEHP.

As a key transcription factor, PXR regulates the expression of the CYP3A4 gene and plays an important role in the metabolic transport and maintenance of the in vivo environment. PXR's regulation of drug-metabolizing enzymes is very extensive, including phase I metabolic enzymes such as CYP3A4, and phase II metabolic enzymes such as UGT and GST [\[46\]](#page-13-0). Du et al. examined several phthalate monoesters for their ability to activate mouse and human PXR [\[47\]](#page-13-1). Male quail were exposed to different doses of DEHP by gavage treatment for 45 d, and the activity of PXR increased in a dose-dependent manner [\[48\]](#page-13-2). In the current study, PXR activity in the DEHP group was lower than that in the control group, but the difference was not significant. The reason why the above experimental results were different from those in the present study might be due to the differences in the total dose, and the duration of DEHP exposure. Our experiment was based on a one-time exposure, while the above exposure was for 45 d. $PXR\alpha$ is the most important retinoid X receptor. PXR could play a regulatory role only in the formation of dimers with PXR_{α} , so the inhibition of PXR may be the reason for the decline in $PXR\alpha$ activity in rats. The activities of PXR and $PXR\alpha$ increased after LBP administration, resulting in the intervention effect on the toxicity induced by DEHP.

4.2. LBP and WJ Intervention after DEHP Exposure

Di(2-Ethylhexyl) phthalate exposure could induce oxidative stress in the liver in a short period of time. The activities of SOD, GSH, and GSH-Px increased abnormally, to resist the oxidative stress, and their activities increased with time. The increase of SOD may have been related to the compensatory increase of SOD activity caused by the accumulation of superoxide free radicals produced by the body itself. The increase of GSH-Px may have been due to the accumulation of hydrogen peroxide produced by the body itself, which lead to the compensatory increase of GSH-Px activity. This was consistent with the results of Wang's study, that DEHP can increase the activities of SOD and GSH-Px, and the level of GSH in the liver of rats [\[49\]](#page-13-3). MDA levels remained in a normal range from day 1 to day 3, then decreased significantly on day 5, and increased significantly on day 7. It was suggested that the content of MDA decreased in the early stage of DEHP exposure due to the self-defense system of rats, while in the later stage, the level of MDA increased due to the failure of SOD and GSH to remove free radicals in time. It was found that the activities of SOD, GSH-Px, GSH, and MDA in rats exposed to DEHP could be reduced by WJ intervention, which indicated that WJ could reduce the oxidative stress caused by DEHP, and its active components could play an antioxidant role; surprisingly, LBP intervention further enhanced the activities of SOD and GSH-Px in rats, and the intervention effect was not as good as that of WJ. In this study, the LBP content in the intervention group was equivalent to 100 mg/kg·bw, so the intervention effect of LBP may have been related to its dosage [\[50\]](#page-13-4). In addition to LBP, *Lycium barbarum* contains antioxidant components such as ascorbic acid, riboflavin, carotene, thiamine, and nicotinic acid, so the LBP of WJ working together with other active ingredients may enhance the intervention effect.

After exposure to DEHP, the activity of GST in hepatocytes was increased. GST could catalyze the nucleophilic addition of reduced GSH with electrophilic organic compounds, which played an important role in the response to oxidative stress. In this study, the up regulation of GST activity may have been due to the compensatory increase caused by the accumulation of electrophilic organic compounds. The content of CYP2E1 and CYP3A1 in WJ was significantly increased on the fifth day after exposure, and the concentration of CYP3A1 was significantly increased by LBP and WJ on the fifth day. These results indicate that continuous intervention could upregulate the content of CYP2E1 and CYP3A1, and then levels returned to normal.

Di(2-Ethylhexyl) phthalate exposure can lead to an abnormal increase of liver metabolic enzymes. To this end, we measured the contents of nuclear receptors RXR and PXR α . Surprisingly, they also showed abnormal increase. $PXR \alpha$ was the most important retinol like X receptor. PXR could play a regulatory role only when it formed a dimer with PXR_{α} , which may be the reason for the same change trend of PXR and PXRα activity after DEHP exposure; there have been similar results before. Di(2-Ethylhexyl) phthalate exposure triggered the aryl hydrocarbon receptor (AhR)/PXR/constitutive androstane receptor (CAR) pathway, and altered the transcription of cerebellar CYP enzymes isoforms in quails [\[47\]](#page-13-1). After LBP intervention, the PXR activity of the rats was significantly higher than that of the control group on the first and third days, and was higher than that of DEHP exposure group on the third day, which may have been due to the synergistic effect of DEHP and LBP. The changes of PXR and $PXR\alpha$ activity after WJ intervention were opposite to that of DEHP, indicating that WJ played a positive role in intervention and regulation.

5. Conclusions

In conclusion, feeding LBP before DEHP exposure, or LBP and WJ after DEHP exposure, improved the hepatotoxicity induced by DEHP, perhaps through increasing the activities of metabolic enzymes in phase I and II regulated by the PXR pathway; and the intervention effect of WJ was more significant. In the future, we will focus on the reasons why WJ works better, and the development of related products.

Author Contributions: H.L.: Methodology, Roles/Writing—original draft, Resources, X.Z.: Validation, Roles/Writing—original draft, S.H.: Software, Project administration, J.Y.: Visualization, Formal analysis, R.L.: Data curation, Investigation, C.L.: Writing—review & editing, Conceptualization, Supervision, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by National Key Research and Development Program of Thirteenth Five-Year Plan (No.2017YFC1601702) and Generic Technique Innovation Team Construction of Modern Agriculture of Guangdong Province (No. 2017LM2152).

Institutional Review Board Statement: All experimental procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All animal tests were approved by the Ani-mal Care Committee of the Laboratory Animal Center of South China Agricultural University, Guangzhou (#SCXK2011-0015).

Data Availability Statement: Datas presented in this study are available on request from the Authors.

Acknowledgments: The authors thank Llion Roberts, from School of Allied Health Sciences and Menzies Health Institute Queensland, Griffith University for valuable opinions and English editing.

Conflicts of Interest: There are no conflicts of interest to declare.

References

- 1. Halden, R.U. Plastics and Health Risks. *Annu. Rev. Public Health* **2010**, *31*, 179–194. [\[CrossRef\]](http://doi.org/10.1146/annurev.publhealth.012809.103714)
- 2. Luo, Y.; Li, X.-N.; Zhao, Y.; Du, Z.-H.; Li, J.-L. DEHP triggers cerebral mitochondrial dysfunction and oxidative stress in quail (*Coturnix japonica*) via modulating mitochondrial dynamics and biogenesis and activating Nrf2-mediated defense response. *Chemosphere* **2019**, *224*, 626–633. [\[CrossRef\]](http://doi.org/10.1016/j.chemosphere.2019.02.142)
- 3. Junaid, M.; Jia, P.; Tang, Y.-M.; Xiong, W.-X.; Huang, H.-Y.; Strauss, P.R.; Li, W.-G.; Pei, D.-S. Mechanistic toxicity of DEHP at environmentally relevant concentrations (ERCs) and ecological risk assessment in the Three Gorges Reservoir Area, China. *Environ. Pollut.* **2018**, *242*, 1939–1949. [\[CrossRef\]](http://doi.org/10.1016/j.envpol.2018.07.067)
- 4. Heinemeyer, G.; Sommerfeld, C.; Springer, A.; Heiland, A.; Lindtner, O.; Greiner, M.; Heuer, T.; Krems, C.; Conrad, A. Estimation of dietary intake of bis(2-ethylhexyl)phthalate (DEHP) by consumption of food in the German population. *Int. J. Hyg. Environ. Health* **2013**, *216*, 472–480. [\[CrossRef\]](http://doi.org/10.1016/j.ijheh.2013.01.001)
- 5. Autian, J. Toxicity and health threats of phthalate esters: Review of the literature. *Environ. Health Perspect.* **1973**, *4*, 3–26. [\[CrossRef\]](http://doi.org/10.1289/ehp.73043)
- 6. Kaul, A.F.; Souney, P.F.; Osathanondh, R. A Review of Possible Toxicity of DI-2-Ethylhexylphthalate (DEHP) in Plastic Intravenous Containers: Effects on Reproduction. *Drug Intell. Clin. Pharm.* **1982**, *16*, 689–692. [\[CrossRef\]](http://doi.org/10.1177/106002808201600908)
- 7. Tickner, J.; Schettler, T.; Guidotti, T.; McCally, M.; Rossi, M. Health risks posed by use of Di2-ethylhexyl phthalate (DEHP) in PVC medical devices: A critical review. *Am. J. Ind. Med.* **2001**, *39*, 100–111. [\[CrossRef\]](http://doi.org/10.1002/1097-0274(200101)39:1<100::AID-AJIM10>3.0.CO;2-Q)
- 8. Koch, H.M.; Bolt, H.M.; Preuss, R.; Eckstein, R.; Weisbach, V.; Angerer, J. Intravenous exposure to di(2-ethylhexyl)phthalate
- (DEHP): Metabolites of DEHP in urine after a voluntary platelet donation. *Arch. Toxicol.* **2005**, *79*, 689–693. [\[CrossRef\]](http://doi.org/10.1007/s00204-005-0004-x) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/16059725) 9. Park, J.D.; Habeebu, S.S.; Klaassen, C.D. Testicular toxicity of di-(2-ethylhexyl)phthalate in young Sprague–Dawley rats. *Toxicology* **2002**, *171*, 105–115. [\[CrossRef\]](http://doi.org/10.1016/S0300-483X(01)00567-4)
- 10. Gao, H.-T.; Xu, R.; Cao, W.-X.; Qian, L.-L.; Wang, M.; Lu, L.; Xu, Q.; Yu, S.-Q. Effects of six priority controlled phthalate esters with long-term low-dose integrated exposure on male reproductive toxicity in rats. *Food Chem. Toxicol.* **2017**, *101*, 94–104. [\[CrossRef\]](http://doi.org/10.1016/j.fct.2017.01.011) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/28089693)
- 11. Koch, H.M.; Drexler, H.; Angerer, J. An estimation of the daily intake of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population. *Int. J. Hyg. Environ. Health* **2003**, *206*, 77–83. [\[CrossRef\]](http://doi.org/10.1078/1438-4639-00205)
- 12. Ito, Y.; Kamijima, M.; Hasegawa, C.; Tagawa, M.; Kawai, T.; Miyake, M.; Hayashi, Y.; Naito, H.; Nakajima, T. Species and inter-individual differences in metabolic capacity of di(2-ethylhexyl)phthalate (DEHP) between human and mouse livers. *Environ. Health Prev. Med.* **2013**, *19*, 117–125. [\[CrossRef\]](http://doi.org/10.1007/s12199-013-0362-6) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/24078404)
- 13. Rhodes, C.; Orton, T.C.; Pratt, I.S.; Batten, P.L.; Bratt, H.; Jackson, S.J.; Elcombe, C.R. Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl) phthalate (DEHP) in rats and marmosets: Extrapolation of effects in rodents to man. *Environ. Health Perspect.* **1986**, *65*, 299–307. [\[CrossRef\]](http://doi.org/10.1289/ehp.8665299) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/3086078)
- 14. Frederiksen, H.; Skakkebaek, N.E.; Andersson, A.-M. Metabolism of phthalates in humans. *Mol. Nutr. Food Res.* **2007**, *51*, 899–911. [\[CrossRef\]](http://doi.org/10.1002/mnfr.200600243) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/17604388)
- 15. Choi, K.; Joo, H.; Campbell, J.L.; Andersen, M.E.; Clewell, H.J. In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. *Toxicol. Vitr.* **2013**, *27*, 1451–1457. [\[CrossRef\]](http://doi.org/10.1016/j.tiv.2013.03.012)
- 16. Eveillard, A.; Lasserre, F.; De Tayrac, M.; Polizzi, A.; Claus, S.; Canlet, C.; Mselli-Lakhal, L.; Gotardi, G.; Paris, A.; Guillou, H. Identification of potential mechanisms of toxicity after di-(2-ethylhexyl)-phthalate (DEHP) adult exposure in the liver using a systems biology approach. *Toxicol. Appl. Pharmacol.* **2009**, *236*, 282–292. [\[CrossRef\]](http://doi.org/10.1016/j.taap.2009.02.008)
- 17. Matic, M.; Mahns, A.; Tsoli, M.; Corradin, A.; Polly, P.; Robertson, G.R. Pregnane X Receptor: Promiscuous regulator of detoxification pathways. *Int. J. Biochem. Cell Biol.* **2007**, *39*, 478–483. [\[CrossRef\]](http://doi.org/10.1016/j.biocel.2006.08.017)
- 18. Wang, L.-Q. Inhibition of Sulfotransferases by Xenobiotics. *Curr. Drug Metab.* **2006**, *7*, 83–104. [\[CrossRef\]](http://doi.org/10.2174/138920006774832596) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/16454694)
- 19. Frank, C.; Makkonen, H.; Dunlop, T.W.; Matilainen, M.; Väisänen, S.; Carlberg, C. Identification of Pregnane X Receptor Binding Sites in the Regulatory Regions of Genes Involved in Bile Acid Homeostasis. *J. Mol. Biol.* **2005**, *346*, 505–519. [\[CrossRef\]](http://doi.org/10.1016/j.jmb.2004.12.003)
- 20. Chung, R.-S.; Chen, C.-C.; Ng, L.-T. Nitrogen fertilization affects the growth performance, betaine and polysaccharide concentrations of Lycium barbarum. *Ind. Crop. Prod.* **2010**, *32*, 650–655. [\[CrossRef\]](http://doi.org/10.1016/j.indcrop.2010.07.021)
- 21. He, N.; Yang, X.; Jiao, Y.; Tian, L.; Zhao, Y. Characterisation of antioxidant and antiproliferative acidic polysaccharides from Chinese wolfberry fruits. *Food Chem.* **2012**, *133*, 978–989. [\[CrossRef\]](http://doi.org/10.1016/j.foodchem.2012.02.018)
- 22. Ho, Y.-S.; Yu, M.-S.; Yang, X.-F.; So, K.-F.; Yuen, W.-H.; Chang, R.C.-C. Neuroprotective Effects of Polysaccharides from Wolfberry, the Fruits of Lycium barbarum, Against Homocysteine-induced Toxicity in Rat Cortical Neurons. *J. Alzheimer's Dis.* **2010**, *19*, 813–827. [\[CrossRef\]](http://doi.org/10.3233/JAD-2010-1280) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/20157238)
- 23. Zhou, Z.-Q.; Xiao, J.; Fan, H.-X.; Yu, Y.; He, R.-R.; Feng, X.-L.; Kurihara, H.; So, K.-F.; Yao, X.-S.; Gao, H. Polyphenols from wolfberry and their bioactivities. *Food Chem.* **2017**, *214*, 644–654. [\[CrossRef\]](http://doi.org/10.1016/j.foodchem.2016.07.105) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/27507521)
- 24. Cheng, C.Y.; Chung, W.Y.; Szeto, Y.T.; Benzie, I.F. Fasting plasma zeaxanthin response to Fructus barbarum L. (wolfberry; Kei Tze) in a food-based human supplementation trial. *Br. J. Nutr.* **2005**, *93*, 123–130. [\[CrossRef\]](http://doi.org/10.1079/BJN20041284)
- 25. Li, X.; Zhou, A. Evaluation of antioxidant activity of the polysaccharides extracted from Lycium barbarum fruits in vitro. *Eur. Polym. J.* **2007**, *43*, 488–497. [\[CrossRef\]](http://doi.org/10.1016/j.eurpolymj.2006.10.025)
- 26. Wu, H.; Guo, H.; Zhao, R. Effect of Lycium barbarum Polysaccharide on the Improvement of Antioxidant Ability and DNA Damage in NIDDM Rats. *Yakugaku Zasshi* **2006**, *126*, 365–371. [\[CrossRef\]](http://doi.org/10.1248/yakushi.126.365)
- 27. Amagase, H.; Sun, B.; Borek, C. Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults. *Nutr. Res.* **2009**, *29*, 19–25. [\[CrossRef\]](http://doi.org/10.1016/j.nutres.2008.11.005)
- 28. Meng, J.; Lu, Z.; Sun, C.; Chang, C. Advances in the pharmacologic of Lycium barbarum polysaccharide. *Lishizhen Med. Mater. Med. Res.* **2018**, *29*, 2489–2493.
- 29. Wu, G.; Jia, Y.; Yuan, S. Progress in immunopharmacology of lycium barbarum anticancer. *China Pharm.* **2002**, *13*, 54–55.
- 30. Miao, T.; Yan, Q.; Wang, J.; Zhang, L. Research progress of lycium barbarum polysaccharide against aging. *Asia Pac. Trad. Med.* **2019**, *15*, 178–180.
- 31. Huang, T.; Zheng, X.; Qiu, X.; Wang, Y. The protective effect of lycium barbarum polysaccharide on model of autoimmune premature ovarian failure in mice. *J. Pharmaceut. Res.* **2014**, *33*, 437–440. [\[CrossRef\]](http://doi.org/10.13506/j.cnki.jpr.2014.08.002)
- 32. Xia, G.; Xin, N.; Liu, W.; Yao, H.; Hou, Y.; Qi, J. Inhibitory effect of Lycium barbarum polysaccharides on cell apoptosis and senescence is potentially mediated by the p53 signaling pathway. *Mol. Med. Rep.* **2014**, *9*, 1237–1241. [\[CrossRef\]](http://doi.org/10.3892/mmr.2014.1964)
- 33. Peng, Q.; Liu, H.; Shi, S.; Li, M. Lycium ruthenicum polysaccharide attenuates inflammation through inhibiting TLR4/NF-κB signaling pathway. *Int. J. Biol. Macromol.* **2014**, *67*, 330–335. [\[CrossRef\]](http://doi.org/10.1016/j.ijbiomac.2014.03.023)
- 34. Liu, F.; Zhang, J.; Xiang, Z.; Xu, D.; So, K.-F.; Vardi, N.; Xu, Y. Lycium Barbarum Polysaccharides Protect Retina in rd1 Mice During Photoreceptor Degeneration. *Investig. Opthalmology Vis. Sci.* **2018**, *59*, 597–611. [\[CrossRef\]](http://doi.org/10.1167/iovs.17-22881)
- 35. Amagase, H.; Nance, D.M. A Randomized, Double-Blind, Placebo-Controlled, Clinical Study of the General Effects of a Standardized Lycium barbarum (Goji) Juice, GoChi™. *J. Altern. Complement. Med.* **2008**, *14*, 403–412. [\[CrossRef\]](http://doi.org/10.1089/acm.2008.0004) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/18447631)
- 36. Li, H.; Zhang, Y.; Liu, L.; Huang, L.; Bai, L.; Jin, S. Effects of DBP on the Structure and Function of Testes in the Male Rats. *J. Beihua Univ.* **2010**, *11*, 9.
- 37. Chen, X.; Wang, J.S.; Jiang, Y. Effects of Co-exposure of Di-(2-ethylhexyl) Phthalate and Benzo(a)pyrene on CYP1A1 and CYP3A4 Enzyme Activities in HepG2 Cells. *Int. J. Occup. Med. Environ. Health* **2011**, *28*, 525–530.
- 38. Court, M.H.; Zhang, X.; Ding, X.; Yee, K.K.; Hesse, L.M.; Finel, M. Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. *Xenobiotica* **2011**, *42*, 266–277. [\[CrossRef\]](http://doi.org/10.3109/00498254.2011.618954) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/21995321)
- 39. Erkekoglu, P.; Zeybek, N.D.; Giray, B.; Rachidi, W.; Kızılgün, M.; Hininger-Favier, I.; Favier, A.; Asan, E.; Hincal, F. The effects of di(2-ethylhexyl)phthalate on rat liver in relation to selenium status. *Int. J. Exp. Pathol.* **2014**, *95*, 64–77. [\[CrossRef\]](http://doi.org/10.1111/iep.12059)
- 40. Doerge, D.R.; Twaddle, N.C.; Churchwell, M.I.; Chang, H.C.; Newbold, R.R.; Delclos, K. Mass spectrometric determination of p-nonylphenol metabolism and disposition following oral administration to Sprague-Dawley rats. *Reprod. Toxicol.* **2002**, *16*, 45–56. [\[CrossRef\]](http://doi.org/10.1016/S0890-6238(01)00198-8)
- 41. Burchell, B.; Nebert, D.W.; Nelson, D.R.; Bock, K.W.; Iyanagi, T.; Jansen, P.L.; Lancet, R.; Mulder, G.J.; Chowdhury, J.R.; Siest, G.; et al. The UDP Glucuronosyltransferase Gene Super family: Suggested Nomenclature Based on Evolutionary Divergence. *DNA Cell Biol.* **1991**, *10*, 487–494. [\[CrossRef\]](http://doi.org/10.1089/dna.1991.10.487)
- 42. Castro-Caldas, M.; Carvalho, A.N.; Peixeiro, I.; Rodrigues, E.; Lechner, M.C.; Gama, M.J. GSTpi Expression in MPTP-Induced Dopaminergic Neurodegeneration of C57BL/6 Mouse Midbrain and Striatum. *J. Mol. Neurosci.* **2008**, *38*, 114–127. [\[CrossRef\]](http://doi.org/10.1007/s12031-008-9141-z)
- 43. He, Y.J.; Huang, S.W.; Liu, R.J.; Liu, C.H. Intervention effects of Lycium barbarum juice on the metabolism of DEHP based on the UGT1 detoxification pathway. *Food. Sci.* **2017**, *38*, 1–8. [\[CrossRef\]](http://doi.org/10.7506/spkx1002-6630-201723031)
- 44. Rataj, F.; Mller, F.J.; Jhne, M.; Zierau, O.; Diel, P.; Vollmer, G.; Kretzschmar, G. Regulation of uterine AHR battery gene ex-pression by 17β-Estradiol is predominantly mediated by estrogen receptor α. *Arch. Toxicol.* **2012**, *86*, 1603–1612. [\[CrossRef\]](http://doi.org/10.1007/s00204-012-0870-y)
- 45. Cao, S.; Du, J.; Hei, Q. Lycium barbarum polysaccharide protects against neurotoxicity via the Nrf2-HO-1 pathway. *Exp. Ther. Med.* **2017**, *14*, 4919–4927. [\[CrossRef\]](http://doi.org/10.3892/etm.2017.5127)
- 46. Hurst, C.H.; Waxman, D.J. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. *Toxicol. Appl. Pharmacol.* **2004**, *199*, 266–274. [\[CrossRef\]](http://doi.org/10.1016/j.taap.2003.11.028)
- 47. Du, Z.-H.; Xia, J.; Sun, X.-C.; Li, X.-N.; Zhang, C.; Zhao, H.-S.; Zhu, S.-Y.; Li, J.-L. A novel nuclear xenobiotic receptors (AhR/PXR/CAR)-mediated mechanism of DEHP-induced cerebellar toxicity in quails (*Coturnix japonica*) via disrupting CYP enzyme system homeostasis. *Environ. Pollut.* **2017**, *226*, 435–443. [\[CrossRef\]](http://doi.org/10.1016/j.envpol.2017.04.015) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/28413083)
- 48. Yang, G.; Zhang, W.; Qin, Q.; Wang, J.; Zheng, H.; Xiong, W.; Yuan, J. Mono(2-ethylhexyl) phthalate induces apoptosis in p53-silenced L02 cells via activation of both mitochondrial and death receptor pathways. *Environ. Toxicol.* **2015**, *30*, 1178–1191. [\[CrossRef\]](http://doi.org/10.1002/tox.21990) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/24706461)
- 49. Wang, S.-F.; Fang, H.-Y.; Qu, H. Optimization of micellar electrokinetic capillary chromatography method using central composite design for the analysis of components in Yangwei granule. *J. Zhejiang Univ. Sci. B* **2011**, *12*, 193–200. [\[CrossRef\]](http://doi.org/10.1631/jzus.B1000135) [\[PubMed\]](http://www.ncbi.nlm.nih.gov/pubmed/21370504)
- 50. Zhong, P.; Ping, L.I.; Zhang, X.L. Effect of angelica Sinensis polysaccharide on the contents of ant-oxidative enzymes and nitric oxide in mice with chemical liver injured. *Modern. Prev. Med.* **2011**, *38*, 4725–4727.